Breaking News

Germany Defeats Argentina for Fourth World Cup Title
Tweet TWEET

CORRECTING and REPLACING: Essilor : Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2013

  CORRECTING and REPLACING: Essilor : Disclosure of Share Capital and Voting   Rights Outstanding as of December 31, 2013    (Pursuant to Article L.233-8 II of the French Commercial Code and articles    221-1 and 223-16 of the General Regulations of the Autorité des Marchés                                  Financiers)  Business Wire  CHARENTON-LE-PONT, France -- January 16, 2014  Regulatory News :   Disclosure of Share Capital and Voting Rights Outstanding as of December 31,                                      2013  As of December 31, 2013, shares and voting rights outstanding of Essilor (Paris:EI), the world leader in ophthalmic optics, broke down as follows:                                                             December 31, 2013 Shares outstanding                                          214,699,498 Exercisable voting rights                                   226,812,217 Total voting rights, based on all outstanding shares,       231,266,623 including shares stripped of their voting rights*  (*) Shares held by the Company.  About Essilor The world’s leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its corporate mission is to enable everyone around the world to access lenses that meet his or her unique vision requirements. To support this mission, the Company allocates more than €150 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Essilor’s flagship brands are Varilux^®, Crizal^®, Definity^®, Xperio^®, Optifog^TM and Foster Grant^®. It also develops and markets equipment, instruments and services for eyecare professionals. Essilor reported consolidated revenue of approximately €5 billion in 2012 and employs around 50,700 people in some 100 countries. It operates 22 plants, more than 400 prescription laboratories and edging facilities, as well as several research and development centers around the world. For more information, please visit www.essilor.com. The Essilor share trades on the NYSE Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. Codes and symbols: ISIN: FR FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.  Contact:  Essilor Investor Relations and Financial Communications Phone: +33 (0)1 49 77 42 16